Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia

[1]  R. Tahar,et al.  Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children. , 2007, Acta tropica.

[2]  J. Lelièvre,et al.  Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  V. do Rosário,et al.  Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola , 2006, Malaria Journal.

[4]  D. Meyrowitsch,et al.  Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. , 2006, Journal of travel medicine.

[5]  M. Grobusch,et al.  Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. , 2005, The American journal of tropical medicine and hygiene.

[6]  M. Mather,et al.  Uncovering the Molecular Mode of Action of the Antimalarial Drug Atovaquone Using a Bacterial System* , 2005, Journal of Biological Chemistry.

[7]  S. Kuhn,et al.  Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. , 2005, The American journal of tropical medicine and hygiene.

[8]  S. Meshnick,et al.  Multiple cytochrome B mutations may cause atovaquone resistance. , 2005, The Journal of infectious diseases.

[9]  T. Jelínek,et al.  Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. , 2004, The Journal of infectious diseases.

[10]  J. Krungkrai.  The multiple roles of the mitochondrion of the malarial parasite , 2004, Parasitology.

[11]  F. Djossou,et al.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  N. Suttorp,et al.  Malarone treatment failure not associated with previously described mutations in the cytochrome b gene , 2004, Malaria Journal.

[13]  M. Muehlen,et al.  Short Communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana , 2004, Tropical medicine & international health : TM & IH.

[14]  P. D. de Vries,et al.  Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam , 2003, Annals of tropical medicine and parasitology.

[15]  L. Basco.  Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis. , 2003, The American journal of tropical medicine and hygiene.

[16]  T. Jelínek,et al.  Malaria Journal BioMed Central , 2003 .

[17]  V. do Rosário,et al.  Review: Genetic diversity of Plasmodium falciparum: asexual stages , 2002 .

[18]  G. Butcher,et al.  Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria , 2002, Malaria Journal.

[19]  D. Overbosch,et al.  Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Kyle,et al.  Plasmodium falciparum: the effects of atovaquone resistance on respiration. , 2001, Experimental parasitology.

[21]  D. Overbosch,et al.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study , 2000, The Lancet.

[22]  Q. Cheng,et al.  Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.

[23]  R. Snow,et al.  Sustainability, affordability, and equity of corporate drug donations: the case of Malarone , 2000, The Lancet.

[24]  B. Lell,et al.  Low-Dose Treatment with Sulfadoxine-Pyrimethamine Combinations Selects for Drug-Resistant Plasmodium falciparum Strains , 1999, Antimicrobial Agents and Chemotherapy.

[25]  Joanne M. Morrisey,et al.  Resistance mutations reveal the atovaquone‐binding domain of cytochrome b in malaria parasites , 1999, Molecular microbiology.

[26]  Akhil B. Vaidya,et al.  A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil , 1999, Antimicrobial Agents and Chemotherapy.

[27]  E. Nagy,et al.  Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. , 1999, The Journal of antimicrobial chemotherapy.

[28]  S. Looareesuwan,et al.  Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. , 1999, The American journal of tropical medicine and hygiene.

[29]  N. Lang-Unnasch,et al.  Alternative Oxidase Inhibitors Potentiate the Activity of Atovaquone against Plasmodium falciparum , 1999, Antimicrobial Agents and Chemotherapy.

[30]  B. Lell,et al.  Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children , 1998, The Lancet.

[31]  F. Gay,et al.  In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. , 1997, The American journal of tropical medicine and hygiene.

[32]  A. Vaidya,et al.  Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite* , 1997, The Journal of Biological Chemistry.

[33]  P. Kremsner,et al.  Atovaquone and proguanil for Plasmodium falciparum malaria , 1996, The Lancet.

[34]  P. Chiodini,et al.  Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. , 1995, The Journal of antimicrobial chemotherapy.

[35]  C. Canfield,et al.  Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. , 1995, Experimental parasitology.

[36]  J. Falloon,et al.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. , 1993, The New England journal of medicine.

[37]  J. Kovacs,et al.  Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS , 1992, The Lancet.

[38]  M. Fry,et al.  Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). , 1992, Biochemical pharmacology.

[39]  J. Le bras,et al.  Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. , 2006, The Journal of antimicrobial chemotherapy.

[40]  A. Björkman,et al.  In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[41]  V. do Rosário,et al.  Genetic diversity of Plasmodium falciparum: asexual stages. , 2002, Tropical medicine & international health.

[42]  H. Webster,et al.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.